Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Pediatrics
Published in: BMC Pediatrics 1/2020

01-12-2020 | Kidney Transplantation | Research article

CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant

Authors: Stefano Turolo, Alberto Edefonti, Luciana Ghio, Sara Testa, William Morello, Giovanni Montini

Published in: BMC Pediatrics | Issue 1/2020

Login to get access

Abstract

Background

We evaluated the role of CYP3A5, ABCB1 and SXR gene polymorphisms in the occurrence of acute kidney rejection in a cohort of pediatric renal transplant recipients.

Methods

Forty-nine patients were genotyped for CYP3A5, ABCB1 and SXR polymorphisms and evaluated with tacrolimus through levels in a retrospective monocenter study.

Results

Patients with the A allele of CYP3A5 treated with tacrolimus had a higher risk of acute rejection than those without the A allele, while patients carrying the homozygous GG variant for SXR A7635GG did not show any episode of acute rejection.

Conclusion

Genetic analysis of polymorphisms implicated in drug metabolism and tacrolimus trough levels may help to forecast the risk of acute rejection and individualize drug dosage in children undergoing renal transplantation.
Literature
1.
Ekberg H, Tedesco-Silva H, Demirabas A, Vitko S, Nashan B, Gurkan A, et al. Reduced exposure to calcineurin inhibitors in renal transplnatation. N Engl J Med. 2007;357:2562–75.PubMedCrossRef
2.
3.
4.
Cole EH, Johnston O, Rose CL, Gill JS. Impact of acute rejection and new-onset diabetes on long-term transplant graft and patient survival. Clin J Am Soc Nephrol. 2008;3:814–21.PubMedPubMedCentralCrossRef
5.
Dunn TB, Noreen H, Gillingham K, Maurer D, Ozturk OG, Pruett TL, et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am J Transplant. 2011;11:2132–43.PubMedPubMedCentralCrossRef
6.
Kuo HAT, Sampaio MS, Vincenti F, Bunnapradist S. Associations of pretranspalnt diabetes mellitus, new-onset diabetes after transplant, and acute rejection with transplant outcomes: an analysis of the organ procurement and transplant network/united network for organ sharing (OPTN/UNOS) database. Am J Kidney Dis. 2010;56:1127–39.PubMedCrossRef
7.
Lebranchu Y, Baan C, Biancone L, Legendre C, Morales JM, Naesens M, et al. Pretransplant identification of acute rejection risk following kidney transplantation. Transpl Int. 2013;27:129–38.PubMedCrossRef
8.
Nickel P, Bestard O, Volk HD, Reinke P. Diagnostic value of T-cell monitoring assays in kidney transplantation. Curr Opin Organ Transplant. 2009;14:426–31.PubMedCrossRef
9.
Snijder PM, van den Berg E, Whiteman M, Bakker SJ, Leuvenink HG, van Goor H. Emerging role of gasotransmitters in renal transplantation. Am J Transplant. 2013;13:3067–75.PubMedCrossRef
10.
Aj M, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, et al. OPTN/SRTR 2012 annual data report: kidney. Am J Transplant. 2014;S12:11–44.
11.
Hesselink DA, van Schaik RH, van der Heiden IP, van der Werf M, Gregoor PJ, Lindemans J, et al. Genetic polymorphism of the CYP3A4, CYP3A5, and MDR1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther. 2003;74:245–54.PubMedCrossRef
12.
Choduri S, Klaassen CD. Structure, function, genomic organization, and single nucleotide polymorphisms of human ABCB1 (MDR1), ABCC (MRP), and ABCG2 (BCRP) efflux transporters. Int J Toxicol. 2006;25:231–59.CrossRef
13.
El-Shair S, Al Shhab M, Zayed K, Alsmady M, Zihlif M. Association between CYP3A4 and CYP3A5 genotype and cyclosporine’s blood levels and dose among Jordanian kidney transplanted patients. Curr Drug Metab. 2019;20:682–94.PubMedCrossRef
14.
Leonard GD, Fojo T, Bates TE. The role of ABC transporters in clinical practice. Oncologist. 2003;8:411–24.PubMedCrossRef
15.
Kotowski MJ, Bogacz A, Bartkowiak-Wieczorek J, Tejchman K, Dziewanowski K, Ostrowski M, et al. Effect of multidrug-resistant (MDR1) and CYP3A4*1B polymorphisms on cyclosporine-based immunosuppressive therapy in renal transplant patients. Ann Transplant. 2019;24:108–14.PubMedPubMedCentralCrossRef
16.
Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull. 2002;25:1391–400.PubMedCrossRef
17.
Sakaeda T, Nakamura T, Okumura K. Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs. Pharmacogenomics. 2003;4:397–410.PubMedCrossRef
18.
Pascussi JM, Drocourt L, Fabre JM, Maurel P, Vilarem MJ. Dexamethasone induces pregnane X receptor and retinoid X receptor-alpha expression in human hepatocytes: synergistic increase of CYP3A4 induction by pregnane X receptor activators. Mol Pharmacol. 2000;58:361–72.PubMedCrossRef
19.
Pascussi JM, Drocourt L, Gerbal-Chaloin S, Fabre JM, Maurel P, Vilarem MJ. Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem. 2001;268:6346–58.PubMedCrossRef
20.
Tirelli S, Ferraresso M, Ghio L, Meregalli E, Martina V, Belingheri M, et al. The effect of Cyp3a5 polymorphism on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients. Med Sci Monit. 2008;14:cr251–4.PubMed
21.
Vanhove T, Annaert P, Kuypers DR. Clinical determinants of calcineurin inhibitor disposition: a mechanistic review. Drug Metab Rev. 2016;48:88–112.CrossRefPubMed
22.
Liu Y, Ji W, Yin Y, Fan L, Zhang J, Yun H, et al. The effects of splicing variant of PXR PAR-2 on CYP3A4 and MDR1mRNA expressions. Clin Chim Acta. 2009;403:142–4.PubMedCrossRef
23.
24.
Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt J, Danhof M, et al. Explaining variability in tacrolimus pharmacokinetics to optimize early exposure in adult kidney transplant recipients. Ther Drug Monit. 2009;31:187–97.PubMedCrossRef
25.
Kurzawski M, Malinowski D, Dziewanowski K, Drozdzik M. Analysis of common polymorphisms within NR1I2 and NR1I3 genes and tacrolimus dose-adjusted concentration in stable kidney transplant recipients. Pharmacogenet Genomics. 2017;27:372–7.PubMedCrossRef
26.
Barraclough KA, Isbel NM, Lee KJ, Bergman TK, Johnson DW, McWhinney BC, et al. NR1I2 polymorphisms are related to tacrolimus dose-adjusted exposure and BK viremia in adult kidney transplantation. Transplantation. 2012;94:1025–32.PubMedCrossRef
27.
Wang ZP, Zhao M, Qu QS, Miao SZ. Effect of pregnane x receptor polymorphisms on tacrolimus blood concentrations and the resulting adverse reaction in kidney transplantation recipients. Genet Mol Res. 2016;15:gmr:15038464.
28.
Akturk S, Erdogmus S, Kumru G, Elhan AH, Sengul S, Tuzuner A, et al. Average tacrolimus trough level in the first month after transplantation may predict acute rejection. Transplant Proc. 2017;49:430–5.PubMedCrossRef
29.
Koitka LPM, Stojanova J, Woillard JP, Monchaud C, Villeneuve C, Essig M, et al. A candidate gene approach of the calcineurin pathway to identify variants associated with clinical outcomes in renal transplantation. Pharmacogenomics. 2016;14:375–91.
30.
Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff ‘09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant. 2010;10:464–71.PubMedCrossRef
31.
Haas M, Sis B, Racusen LC, Solez K, Glotz D, Colvin RB, et al. Banff meeting report writing committee Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant. 2014;14:272–83.PubMedCrossRef
32.
Turolo S, Tirelli AS, Ferraresso M, Ghio L, Belingheri M, Groppale E, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep. 2010;62:1159–69.PubMedCrossRef
33.
Parajuli S, Joachim E, Alagusundaramoorthy S, Aziz F, Blazel J, Garg N, et al. Donor-specific antibodies in the absence of rejection are not risk factor for allograft failure. Kidney Int Rep. 2019;45:1057–65.CrossRef
34.
35.
Yin S, Song T, Lin X, Xu H, Zhang X, Jiang Y, et al. Non-linear relationship between tacrolimus blood concentration and acute rejection after kidney transplantation: systematic review and dose-response meta-analysis of cohort studies. Curr Pharm Des. 2019;25:2394–403.PubMedCrossRef
36.
Salcedo-Herrera S, Pinto Ramirez JL, Garcia-Lopez A, Amaya-Nieto J, Giron-Lugue F. Acute rejection in kidney transplantation and early beginning of tacrolimus. Transplant Proc. 2019;51:1758–62.PubMedCrossRef
37.
Hu R, Barratt DT, Coller JK, Sallustio BC, Somogyi AA. Is there a temporal relationship between trough whole blood level tacrolimus concentration and acute rejection in the first 14 days after kidney transplantation? Ther Drug Monit. 2019;41:528–32.PubMedCrossRef
38.
Zhang J, Kuehl P, Green ED, Touchman JW, Watkins PB, Daly A, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics. 2001;11:555–72.PubMedCrossRef
39.
Banerjee M, Robbins D, Chen T. Targeting xenobiotic receptors PXR and CAR in human disease. Drug Discov Today. 2015;20:618–28.PubMedCrossRef
40.
Taiplae M, Krykbaeva I, Koeva M, Kayatekin C, Westover KD, Karras GI, et al. Quantitative analysis of Hsp90-client interactions reveals principles of substrate recognition. Cell. 2012;150:987–1001.CrossRef
41.
42.
Taiplae M, Jarosz DF, Lindquist S. HSP90 at the hub of protein homesotasis: emerging mechanistic insights. Nat Rev Mol Cell Biol. 2010;11:515–28.CrossRef
43.
Billing H, Hocker B, Fichtner A, Van-Damme-Loamberts R, Friman S, Jaray J, et al. Single-nucleotide polymorphism of CYP3A5 impacts the exposure to tacrolimus in pediatric renal transplant recipients: a pharmacogenetics substudy of the TWIST trial. Ther Drug Monit. 2017;39:21–8.PubMedCrossRef
44.
Lapeyrague AL, Kassir N, Theoret Y, Krajinovic M, Clermont MJ, Litalien C, et al. Conversion from twice- to once-daily tacrolimus in pediatric kidney recipients: a pharmacokinetic and bioequivalence study. Pediatr Nephrol. 2014;6:1081–8.CrossRef
45.
Cattaneo D. Pharmacogenetics of immunosuppressants: progress, pitfalls and promises. Am J Transplant. 2008;8:1374–83.PubMedCrossRef
46.
Metadata
Title
CYP and SXR gene polymorphisms influence in opposite ways acute rejection rate in pediatric patients with renal transplant
Authors
Stefano Turolo
Alberto Edefonti
Luciana Ghio
Sara Testa
William Morello
Giovanni Montini
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Pediatrics / Issue 1/2020
Electronic ISSN: 1471-2431
DOI
https://doi.org/10.1186/s12887-020-02152-3

Other articles of this Issue 1/2020

BMC Pediatrics 1/2020 Go to the issue

Research article

Combination of gamma-glutamyl transferase and liver stiffness measurement for biliary atresia screening at different ages: a retrospective analysis of 282 infants

Research article

Comparison of child and family reports of health-related quality of life in pediatric acute lymphoblastic leukemia patients after induction therapy

Research article

Allowing more time to ILCOR Step A of neonatal resuscitation leads to better residents’ task completion in simulated scenarios. A problem of time pressure?

Research article

Laparoscopic orchiopexy of palpable undescended testes_ experience of a single tertiary institution with over 773 cases

Research article

Lacrimal sac bacteriology and susceptibility pattern in infants with congenital nasolacrimal duct obstruction in the 1st year of life: a cross-sectional study

Case report

Spinal epidural hematoma without significant trauma in children: two case reports and review of the literature